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Focus on “At-Risk” Individuals
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In individuals at-risk of developing inflammatory arthritis, the value of an ultrasound (US)
scan assessment to predict progression has been demonstrated repeatedly. However,
depending on recruitment criteria, these individuals may be at different stages in the
arthritis development continuum, therefore representing a heterogeneous population. As
a consequence, the predictive value of ultrasound results may differ between cohorts.
As other reviews have focused on the challenges in population recruitment or have
combined biomarkers predicting value according to one recruitment pathway, we wanted
to focus on the sole use of ultrasound assessment and its variation according to
population recruitment criteria. In this review, we discuss the use of ultrasound in the
different at-risk populations across the inflammatory arthritis disease continuum. This
review demonstrates that although some sub-population data is scarce, ultrasound is
best predictive in three at-risk populations: those with a positive ACPA test in the context
of non-specific MSK symptoms, those with clinically suspect arthralgia and those with
palindromic rheumatism. We consider that ultrasound assessment will be a cornerstone
in prediction risk modeling and prevention studies of the preclinical phases of IA in
the future.
Keywords: arthritis (including rheumatoid arthritis), ultrasound, at risk, prediction, ACPA, anti-cyclic citrullinated
peptide antibodies
INTRODUCTION
Since the availability of biologic therapies, rheumatology practice has entered a new era where
achieving damage free remission in rheumatoid arthritis (RA) is not only feasible, but common.
As early treatment decreases long term joint damage and impaired quality of life, much effort has
been made to refer, diagnose and treat patients early (1). We are now evolving toward the next
stage of inflammatory arthritis management: prevention. The new priority is to identify individuals
that might eventually develop inflammatory arthritis (IA): the “At-risk” individuals and treat them
before arthritis occurs thereby preventing progression to RA. At-risk individuals with subclinical
inflammation are at increased risk of arthritis development. It is therefore logical to suggest that
this population should be considered for treatment, therefore should be included in the “window
of opportunity” (2).
One of the many challenges is that arthritis development is a late step in a long process
sometimes called “the inflammatory arthritis disease continuum” (3), where the preclinical phase
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includes, genetic, environmental, and systemic factors
which may arise years before arthritis occurs (4, 5). When
recruited into research cohorts, at-risk individuals might be
at different stages of the continuum therefore representing
heterogeneous populations, with differing risks of progression
to IA.
In this review, we discuss the use of ultrasound (US) in
the different at-risk populations across the arthritis disease
continuum (see Figure 1). The populations in which US may be
most informative will be discussed. We included peer-reviewed,
published research including, retrospective and prospective
analyses, observational, and interventional studies that were
relevant for research and clinical practice. Only articles in English
language were included.
US Findings in Healthy Subjects
As the aim of this review is to describe the evidence of US
abnormalities in the preclinical phase of IA, it seems important to
first consider their prevalence in healthy subjects. A first analysis
found a power Doppler (PD) signal in 11% of hands and wrists
of 27 healthy volunteers, especially in the wrists (6). Using the
OMERACT consensus, analysis of 127 healthy controls (HC)
matched with another 127 patients with early arthritis from the
ESPOIR cohort found that 11% of the MCP joints 2–4 and fifth
MTP joints analyzed had bone erosions (BE), 22% had synovial
hypertrophy (SH)≥ grade 1 and 9%≥ grade 2 (7). Another study
showed high prevalence of SH grade 1 in healthy subjects (15%)
as well as in RA patients (56%), and no association with PD,
tenderness or swelling, suggesting that only Grade ≥ 2 should be
considered pathological (8). This is also suggested by a analysis
on 46 young healthy subject who showed SE in almost 20% of
them (9).
The most comprehensive analysis included 32 joints of 207
HC subjects (6,621 joints in total) (10), showing that the
prevalence of US abnormalities was low at joint level but high
FIGURE 1 | Evolution toward rheumatoid arthritis (RA) can be considered as a disease continuum encompassing pathogenic phases which conclude in the
development of arthritis. Preclinical phases can comprise of a symptomatic at-risk individuals with genetic risk (e.g. an affected first degree relative), environmental risk
(including smoking and mucosal inflammation), and RA-related systematic autoimmunity (e.g. ACPA antibodies). Subclinical synovitis is more often found in
symptomatic at-risk individuals, either in the presence of RA associated autoantibodies, or clinically suspect arthralgia (CSA).
at individual level 9 vs. 88%), and most commonly synovial
effusion (SE) (69% of joints with an abnormality). BE were found
only in first metatarso-phalangeal (MTP1) joints (n = 4) and
always with PD. The most prevalent joints with US findings were
the MTP1 joints followed by MTP joints 2 to 5, then wrists,
metacarpo-phalangeal (MCP) joints (especially the third), and
finally proximal inter-phalangeal (PIP) joints which were almost
never involved. Grade 1 was the most commonly score found,
higher grades were only found in feet (10). Grade 1 SE and SH
were highly prevalent in healthy subjects, the authors suggested
excluding these parameters from the OMERACT ultrasound
protocols (7, 10). None of the analyses showed differences
between men and women. Only one study showed significant
effect of age, especially in the feet (10). While all of the above
studies used semi-quantitative measurement, another analysis
of 78 individuals determined quantitative measurement of the
radio-carpal abnormalities with a greater chance to indicate
RA (11).
Taken together the above studies suggest that the presence
of low grade US abnormalities (especially grade 1 SE and SH
and feet localization) are often present and therefore should
not be considered pathognomonic for inflammatory arthritis.
It is interesting to notice differences between each MTP, the
first and fifth showing the most abnormalities and that larger
joints such as elbows, ankles and shoulders have not been
analyzed. Also, midfoot joints are not considered in any of
the studies. The EULAR-OMERACT combined score defined
synovitis as both PD and GS≥1 (GS including SH and SE),
including only small joints, with no difference of scoring between
joints (12).
The Use of US in First Degree Relatives of
Patients With RA
Because a family history of RA has been shown to
increase the risk of developing this disease, the use of
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US as a prediction tool for the development of arthritis
in first degree relatives (FDRs) of RA probands has
been investigated.
A small study of 20 patients with RA and 25 of their FDRs was
undertaken to explore the presence of abnormal US findings in
FDRswithout clinical arthritis (13, 14). Eight FDRs had arthralgia
symptoms, but all were negative for RF and ACPA. The study
confirmed the presence on US of inflammatory activity in FDRs
(10/25 patients, 40%) and offers support for the use of US as a
screening tool in this at-risk population. This study was limited
by the small number of participants and did not present the US
findings in detail.
A large prospective study investigated a cohort of 237 FDRs
of RA patients (15). The population included a spread across
the spectrum of RA development and was classified into four
groups (three preclinical and one clinical). The first group were
those “without risk factors,” meaning those negative for the
shared epitope, anti-citrullinated protein antibody (ACPA) or
rheumatoid factor (RF) and had no symptoms of possible RA (n
= 45). The second group had risk factors, with either presence
of one or two copies of the shared epitope or an ACPA positive
test but no symptoms associated with possible RA (n = 38).
The third group included subjects with inflammatory arthralgia,
or self-reported symptoms associated with possible RA (n =
132) and the fourth group had features of unclassified arthritis
(UA) (n = 58). The authors found that active US findings were
associated with the presence of UA on examination but not
with the earlier preclinical phases of RA development, including
those who had genetic risk factors but were asymptomatic. There
was no statistical significance between the US results of ACPA
positive and negative FDRs, however it is worth noting that the
US scores for these groups were quite low, [mean B-mode score
(SD): 6.7 (3.6) vs 6.8 (3.6)], OR: 1.0 (95% CI: 0.9 to 1.1); mean
Doppler score (SD): 0.8 (1.3) vs. 1.2 (1.9), OR: 1.2 [95% CI: (0.9
to 1.6]). In addition, there were no demographic or clinical risk
factors significantly associated with active US findings except for
older age.
These results do not support a role for US in FDRs without
symptoms, as part of a screening strategy for preclinical RA
detection in FDRs, with the possible exception of those with UA
features. Further analysis on the individuals who are positive
with the shared epitope and/or an ACPA tests would improve
categorizing risk populations.
The Use of US in Individuals With Clinically
Suspect Arthralgia
Other studies have explored the use of ultrasound in predicting
IA in patients with clinically suspect arthralgia (CSA).
CSA was defined by EULAR as a set of characteristics
to be used in patients with arthralgia without clinical
arthritis and without other diagnosis or explanation for the
arthralgia (16).
Although many of the following studies were performed prior
to this definition, they do follow the same theme of including
patients who had inflammatory arthralgia but had no clinical
synovitis (CS). An example of this is a large multicentre study
which included patients who presented with at least two painful
joints but no CS, with symptoms that lasted less than a year (17).
Of the 196 patients who were included, 159 patients completed
follow up over a 1 year period, only 15%were ACPA positive. The
authors defined US synovitis as GS≥ 2 and PD≥ 1 and reported
a statistically significant association between US synovitis and
prediction of IA (OR 3.03, 95% [CI: 1.69–5.41]). They concluded
that the lack of US synovitis was a strong negative predictor
for IA. These findings were further supported by a retrospective
analysis of 80 consecutive patients using SONAR B-mode criteria
to determine significant synovitis (18, 19). They found that
significant US GS synovitis appeared to be the only independent
predictor of RA on multivariate analysis (OR 7.4 [95%CI: 1.19–
42.8]) in ACPA negative patients who presented with poly-
arthralgia and no CS.
A recent study compared the US and MRI results of 70
individuals with CSA (n = 40) and early IA (n = 30). They
showed an overall significant correlation between both imaging
techniques regarding synovitis and tenosynovitis, especially
in the MCP and wrists joints, although MRI was more
sensitive. Although less frequently present in the CSA subgroup,
similar results of concordance were found, but with a lower
sensitivity (20).
Thus, the literature would suggest that US does add additional
value to clinical and laboratory investigations in predicting IA
in those with CSA. However, there are a paucity of data on
US as MRI has been preferred and further US investigation
is recommended.
The Use of US in ACPA (and/or RF) Positive
Individuals With Musculoskeletal
Symptoms
There have been various studies on the use of US to predict RA
in at-risk populations who have been selected on the base of
an ACPA and/or RF positive, with MSK symptoms (including
arthralgia), but no CS.
An important observational cohort study investigating US
as a predictor for IA in ACPA positive at-risk individuals was
conducted by a group in Leeds (21). The 100 consecutive
participants included were ACPA positive, had a new non-
specific musculoskeletal (MSK) symptom, but no CS. They
demonstrated in multivariable analysis a significant association
between PD at the patient level and the development of
IA (HR 1.88 [95% CI 1.07–3.29]) and incorporated it in a
prediction model including serological and clinical measures. In
Amsterdam, a prospective cohort study of 192 participants who
were ACPA and/or RF positive, found that Gray Scale (GS) and
PD were predictive for IA at the joint level, but this did not
reach statistical significance at the patient level, meaning that
there was a significance in US findings predicting which joint
would progress to clinical arthritis, but not which patients would
progress to IA (22). It is useful to note that US protocols varied
between both studies; while Amsterdam’s US protocol included
only painful, adjacent, and contralateral joints if hands were
involved, the Leeds study included all MCP joints, PIP joints and
both wrists. A follow up study in Leeds included 136 individuals
and added MTP joints to the analysis (23), they concluded that
all US findings (BE grade ≥ 1, GS grade ≥ 2 and PD grade ≥ 1)
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could predict progression to IA and its timing, with the risk being
greatest in those patients with at least one joint with PD signal
on US. Unlike the Amsterdam cohort, the predictive value of PD
was significant at both the joint and patient level. The discrepancy
in findings may have been due to the differing inclusion criteria
in the studies. While the Amsterdam cohort included about a
third of RF positive—ACPA negative individuals, Leeds group
included only ACPA positivity, suggesting that individuals in the
two cohorts could have been at different level of progression risk.
Additionally, the US protocols in both studies were different,
Leeds scanned 32 joints including bilateral wrists, MCPs, PIPs
and MTPs. Both studies were amongst the first to include only
patients without CS.
A follow up prospective cohort study from Amsterdam (24)
included a cohort of 163 seropositive (RF and/or ACPA) patients
who had arthralgia but no CS in a prospective cohort. After
excluding metatarsophalangeal joints (MTPs), they showed that
GS had a significant predictive value to progression to IA (OR
6.6 [95%CI 1.9–22]). Unlike the other above studies, PD was not
found to be predictive in this study. The authors attributed this
main difference to the alternative scanning protocol and technical
differences in US machines. Differences can also be ascribed
to the inclusion criteria, as Nam et al. included ACPA positive
patients only (18).
In two further analyses, the first (25) analyzed US images from
319 patients and found that the number of joints with PD or
tenosynovitis (TSV) was predictive of progression to IA with
high specificity and moderate sensitivity with respective hazard
ratios of 1.2 (p = 0.026) and 1.13 (p = 0.025), the addition
of ACPA titer improved the predictive value of the number of
joints with PD with a specificity/sensitivity of 0.92/0.34 (AUC
0.964). The authors also suggested that a selection of joints—
mainly in the hands and feet—with better predictive power could
improve US sensitivity. Another multivariable analysis on the
same population (n = 488) showed that individuals with 1–
3 joints with a PD signal or 1–2 with BE were twice as likely
to develop IA, those with ≥ 4 joints with a PD signal were
more than six times more likely (26). A more recent study (27)
analyzed baseline US scans of a further 419 CCP positive at-risk
individuals from the Leeds CCP cohort. In this analysis, the most
predictive features for the development of clinical arthritis on US
were BE in >1 joint or BE combined with synovitis in the MTP5
joint (OR 10.6 [95% CI 1.9 to 60.4] p < 0.01) and 5.1 [95% CI
1.4 to 18.9] p = 0.02] respectively. While presence of BE in any
joint was previously described predictive of progression to IA
(23), this study suggests that some joints might be more specific
for progression.
Overall, the discrepancies in some of the findings are likely
due to population variability: whether selected individuals are
tested positive for RF and/or ACPA, associated symptoms and set
of joints analyzed, but also the factors around how to perform
the US itself, defining US synovitis, the optimum number and
specific joints to be incorporated in the US protocol and the use
of different scoring systems.
The above studies demonstrate that there is strong evidence
that all US features including GS, BE, TSV, and especially PD
presence, have an important part to play in predicting IA in
seropositive at-risk individuals with MSK symptoms. They also
discussed scanning protocols, while a limited, focused joint set
can be used to identify erosions and predict arthritis; pragmatic
scanning protocol could be easily incorporated into clinical
practice. Ideally future studies should use standardized US
protocols and scoring systems.
The Use of US in Individuals With
Palindromic Rheumatism
Some individuals—ACPA positive or not—present with
intermittent inflammatory flares, alternating between short
attacks of pain and swelling and asymptomatic periods. Specific
clinical and US features found in these individuals suggest that
palindromic rheumatism (PR) could be a discrete pathological
entity (28). However, shared risk factors with RA suggest PR
could also be considered a phase of the RA continuum (3).
Different studies have focused on this population, whether it
be during or in-between flares of joint symptoms. In all these
analyses, the proportion of ACPA positive patients ranges
between 13 and 66.7%.
In 2014, a group analyzed 11 joints in the hands of 54 patients
outside of a flare (29). The joints reported to be involved in the
first flare varied according to ACPA status, with an increased ratio
of small joints involvement in ACPA positive participants. This
antibody based discrepancy was confirmed on US performed
between flares. At the joint level, they found that only 2.8%
of the 1,188 joints analyzed had SH≥2, with PD≥1 in 1.4%
of these, mostly wrists and MCP. At the patient level, 25.9%
of them presented US synovitis in at least one joint (SH≥2,
or PD≥1). Patients in this cohort had long disease duration
(mean duration of 11.6 years) and 61.1% were on DMARDs
(mainly hydroxychloroquine). Ten patients of this study were
also assessed during a flare, none of them showed periarticular
US abnormalities, seven showed an intra-articular PD signal.
In a small cohort (n = 15), analysis of US scans taken during
flares in the hands and wrists showed US synovitis in 60% of
individuals (n = 9/15), with PD in 6 of them (30). The largest
analysis to date was based on 84 PR patients during a flare (31).
While 78% of the participants had signs of PD presence, only 31%
of these were intra-articular PD, the rest were features of TSV
and/or periarticular soft tissue inflammation. Moreover, Intra-
articular PD presence and ACPA positivity were both recognized
as predictors of progression to RA (respectively: OR = 2.28
[95%CI: 0.67–7.68] and OR= 6.18 [95% CI: 1.50–25.52]).
The most recent imaging analysis in PR was performed on 79
individuals comparing US and MRI (32). This analysis was the
first to include treatment-naïve individuals, with a short duration
of symptoms. The authors compared US examinations taken
during and between flares, and showed US of the flaring area
showed significantly more TSV (23 vs. 4%), more signs of extra-
capsular inflammation (61 vs. 15%), particularly periarticular
inflammation (39 vs. 4%), (and non-significantly different PD
synovitis [23 vs. 7%]) than in-between flares. Interestingly, there
was no influence of the antibody status on the US features.
These results suggest that palindromic rheumatism has a discrete
imaging phenotype and that some features such as ACPA
positivity and intra-articular inflammation during a flare may
increase the risk of developing RA.
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These studies all included individuals with PR, which US
has revealed some specific features such as higher proportion
of extra-capsular abnormalities compared to at-risk and RA
individuals. Discrepancies can be explained by recruitment
criteria differences such as the use of previous medication,
proportion of ACPA positive individuals and symptoms
duration. Two analyses showed predominance of US extra-
articular inflammation while all showed presence of sub-
clinical inflammation.
Ultrasound in Undifferentiated Arthritis
Early diagnosis is a priority, it is therefore essential to improve
diagnostic success rates at first referral. Because of its power and
accessibility, US is now recognized as an essential tool for IA
diagnosis and management. We have discussed US findings and
implication in individuals with no CS (the at-risk populations),
individuals with intermittent CS (palindromic rheumatism).
Here we discuss how US use has been a major tool in assessing
patients at CS onset. This chapter will not focus on RA patients
but those with undifferentiated arthritis (UA) who are presenting
with early CS but do not meet classification criteria for a specific
rheumatic disease.”
Many studies have shown US superiority to clinical
examination in detecting synovitis (33–35). In a cohort of
50 ACPA and RF negative patients with UA from early arthritis
clinics, they showed that IA probability increased from 6 to
8–85% depending on which two US features were present (GS =
3, PD ≥ 1 or BE presence) (36). This was confirmed in a large
study (n = 831) where 31% of patients progressed to persistent
IA, baseline serological and clinical biomarkers were already
predictive of progression, but US improved all predictive values,
particularly in the seronegative patients (AUC increase of 9%, p
< 0.001) (37). Another study focused on EULAR classification
criteria for RA, with the same recruitment criteria (n = 109),
61% of participants presented with a swollen joint, 30% were
ACPA+ (compared to 15.4% in the previous study). They
showed that GS≥1 improved the sensitivity of the 2010 criteria
from 58 up to 78% without decreasing specificity (AUC 0.868),
which was 93.7% if GS ≥ 2 or PD ≥ 1 were present, but at the
price of decreased specificity which went down to 56.1% (AUC
0.844) (38). US was also shown to be especially useful in RA
diagnosis in CCP negative very early UA. Indeed, in a study
recruiting only CCP negative individuals with suspected UA,
US synovitis significantly improved the sensitivity of the 2010
classification criteria up to 86.2% (39), meaning that US could
counterbalance the absence of specific serology findings. While
using a probabilistic approach depending on the practitioner’s
impression, another group showed that the addition of US to
routine investigations increased the diagnostic certainty of UA
from 31.1 to 61.2% (p < 0.001) (40). It is interesting that in these
studies, more than half of patients presented abnormalities on
first US but not all developed a persistent disease, suggesting that,
focusing on the most specific US features such as PD presence
and/or GS ≥ 2 might improve US accuracy. Another study
showed that GS was more effective at showing synovitis than
clinical examination, laboratory investigation (p = 0.00015), and
plain film radiography (p = 0.0002) (41). In a study recruiting
individuals with at least one swollen joint, the same improvement
of the AUC for RA diagnosis was found, they also showed that
MCP joints were highly specific for IA (42). Others found that
selecting PD grade 2 increased discriminative ability (43).
Interestingly, in a large (n = 379) retrospective analysis
on a cohort of patients referred to early arthritis clinic and
followed for minimum 12 months, US parameters did not show
significant predictive value for persistent IA in comparison
to clinical parameters alone, (AUC curve both metrics: 0.91;
[95% CI 0.89–0.94] [95% CI 0.88 to 0.94] respectively) (44).
This same group did a further study with different scanning
protocol and comparison methodology between clinical and US
variables, which did show improvement of predictive values
when comparing to clinical parameters alone (37).
The same team developed two “risk metrics” computerized
tools using logistic regression to predict the development of
persistent IA whereas the first models used multivariate and
ROC curve analysis to identify discriminators of IA and the
added value of US parameters (44). Another diagnostic model for
progression from UA to RA was designed combining symptoms
and morning stiffness durations, raised inflammatory markers,
CCP and or RF positivity and PDUS presence in 1, 2 or≥3 joints,
which provided an impressive AUC of 0.919 (n= 149) (45).
After a RA diagnosis has been made, US has also shown
a good correlation with composite scores of disease activity
at all points of disease evolution, as well as with radiological
damage (33, 46–48). It is suggested for use in the assessment
of remission, prediction of flares, and to assess risk of relapse
when tapering treatment as well as to inform the need to
intensify treatment (49–55). PROMPT trial randomized 110UA
individuals to receive methotrexate (MTX) vs. placebo for 1 year
depending on US results. At 5 years, they showed no difference in
progression rates to RA, only a delay in progression in the treated
ACPA positive participants (56).
Overall, US has proved its place in diagnosis, disease activity
and remission assessment while, for now, US driven trials have
shown variable results.
DISCUSSION
The main challenge in populations at-risk of RA is to categorize
biomarkers that are specific, sensitive, and reproducible in
predicting disease progression. Some of them may be present
years before progression and remain stable—such as specific
antibodies or genetic predisposition—whilst others may vary
with time or only appear closer to the clinical phase of the
disease such as abnormalities on high-resolution imaging, for
example, US. Defining the phase where sub-clinical inflammation
on imaging appears is particularly important, as it represents the
initial onset of articular inflammation and as such, the phase
where clinical arthritis is imminent. Indeed, as one RCT has
shown to delay the onset of RA (57), the preclinical phase of
RA could be the optimal time point to initiate treatment as
damages have not occurred yet, thus re-defining the window of
opportunity. Delaying or even preventing the onset of RA will
have major social, financial, and personal impact on patients
and society.
Retrospective studies on RA patients were highly useful
initially to find out biomarkers that were present before
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symptoms, but these are limited in the quantity and quality of
the data. For example, not all analysis was possible on frozen
blood samples, no imaging was performed, and clinical data
were absent. Therefore, observational studies on RA prediction
should now be all prospective. Another important challenge in
at-risk population studies are the discrepancies between and
within cohorts depending on the recruitment criteria. This
implies that results are difficult to replicate and/or compare
between populations. We discussed above the various pathways
of prospective recruitment, for example, CSA and ACPA+
individuals, with a usual progression to IA rate of around one
third of participants. This low progression rate increases duration
of follow-up needed, tests and visits to be repeated, and the need
for large cohorts to get significant results. Only a few centers are
able to support this.
Identifying individuals who would benefit the most from an
US assessment is of major importance. Indeed, although US
sub-clinical inflammation can be found throughout the whole
disease continuum toward RA, US abnormalities have shown—
at present—only of predictive value for disease development in
specific populations. The most representative are symptomatic
at-risk individuals who have been identified by antibody
positivity while in some populations, for example, in FDRs
and CSA individuals, data are sparse and would benefit from
further study. Another limitation is that not all analysis used
the same US protocols. Even if we nowadays tend to follow
EULAR/OMERACT recommendation, this has not always been
the case. Although some US protocols focusing on specific joint
sets are suggested in RA to improve US pragmatic use in clinic
(58, 59), no joint based analysis have been performed on at-risk
individuals yet. Nevertheless, focus is often on the small joints
such as MCP, PIP, MTP, and wrists.
The studies investigating the role of US in FDRs do not
support its use in those without symptoms. There is however a
paucity of data in this area and further exploration is needed. On
the other hand, the predictive value of US for IA development
was greater in the individuals with MSK symptoms identified
by a positive ACPA test. In this group particularly, depending
on the US scan protocols and the recruitment criteria, US
features have shown significant predictive value at the joint
and patient level, for GS, BE, TSV, and especially for PD
presence. This is more consistent if we consider the studies
of individuals with more stringent inclusion criteria, with
cohorts more likely to be at imminent risk of progression. In
individuals with CSA, MRI-US comparison has shown good
correlation, mainly for specificity. At diagnosis of early UA, some
studies showed US superiority to clinical examination, efficacy
in RA diagnosis, disease activity assessment, and treatment
efficacy. In this population, efficacy is not dependent on the
serological results and might be of more value in the seronegative
individuals. It has good discriminative value, improving the
classification criteria’s sensitivity. In established RA, although it
has been shown to be a good predictor in treatment response,
remission assessment, and flare prediction, two trials comparing
conventional T2T approach with US lead approach did not
show significant differences in DAS28 remission, and lead to
an increased treatment regimen is the US groups (60, 61).
Nevertheless, secondary analysis showed that Boolean remission
was more often reached in the US arm (61).
At present without guidance, rheumatologists have different
approaches to managing at-risk individuals. A survey conducted
in 2019 across the UK showed that 73% of practitioners would
treat ACPA positive individuals if at least one joint showed
PD presence on US (62). This reflects the pragmatic approach
used due to the lack evidence on which treatment is the most
appropriate, which population would respond well and what
is the most appropriate timing to start treatment. This lack of
global consensus emphasizes the need for research studies to
assess these questions (63). Although individuals followed in
preventive observational cohorts showed milder disease activity
at progression (64), long term impact of prevention clinics
have not been assessed yet. A few randomized controlled trials
have been designed on individuals without CS. While one used
the presence of US inflammation as part of the recruitment
criteria (57), another one collected US data along the study for
secondary analysis, results are not published yet (65), none of the
others included US as an outcome or collected longitudinal data
(66–68). Some RA treatments have been tested on individuals
with UA (56) or even before CS occurs (65), the complexity
here is to define the optimal high risk individuals who may
benefit from treatment as well as the participant acceptance for
a medication without confirmed disease (69, 70). At present,
no formal economic analyses for use of US or treatment in at-
risk individuals have been conducted, it therefore represents an
important area for future work.
All aspects of US findings throughout the RA continuum
have shown its high predictive value for progression to clinical
synovitis, perhaps with PD standing out to be most predictive.
However, it is difficult to compare these aspects due to the
different definitions of US synovitis and scanning protocols
through the studies. Overall, US does offer clear assistance in
identifying sub-clinical inflammation in individuals at-risk of IA.
However, we have to consider the time and resources needed
for systemic prevention to be put in place. All populations
considered, it appears that the greatest impact on IA prediction
of US examination can be found in three at-risk populations:
those with a positive ACPA test in the context of non-specific
MSK symptom, those with CSA, and those with palindromic
rheumatism. Since it has shown such good predictive value
in IA and in the preclinical phases of IA, it is expected that
US will be a cornerstone in prediction risk modeling and
prevention studies. Nonetheless, further studies with unified
selection criteria, specific joints and/or feature selections are still
needed to improve US impact relevance.
AUTHOR CONTRIBUTIONS
LD and RC have participated with equal contribution and would
like to share first authorship. KM: important part in topic choices,
discussion, proof reading, and time input. PE: topic choices,
discussion, and final approval for submission. All authors
contributed to the article and approved the submitted version.
Frontiers in Medicine | www.frontiersin.org 6 October 2020 | Volume 7 | Article 587827
Duquenne et al. Ultrasound in At-Risk individuals
REFERENCES
1. Nell VP, Machold KP, Eberl G, Stamm TA, Uffmann M, Smolen JS. Benefit
of very early referral and very early therapy with disease-modifying anti-
rheumatic drugs in patients with early rheumatoid arthritis. Rheumatology.
(2004) 43:906–14. doi: 10.1093/rheumatology/keh199
2. Burgers LE, Raza K, van der Helm-van Mil AH. Window of
opportunity in rheumatoid arthritis—definitions and supporting
evidence: from old to new perspectives. RMD Open. (2019) 5:e000870.
doi: 10.1136/rmdopen-2018-000870
3. Mankia K, Emery P. Palindromic rheumatism as part of the
rheumatoid arthritis continuum. Nat Rev Rheumatol. (2019) 15:687–95.
doi: 10.1038/s41584-019-0308-5
4. Nielen MM, van Schaardenburg D, Reesink HW, van de Stadt RJ, van der
Horst-Bruinsma IE, de Koning MH, et al. Specific autoantibodies precede the
symptoms of rheumatoid arthritis: a study of serial measurements in blood
donors. Arthritis Rheum. (2004) 50:380–6. doi: 10.1002/art.20018
5. Silman AJ, Hennessy E, Ollier B. Incidence of rheumatoid arthritis in
a genetically predisposed population. Brit J Rheumatol. (1992) 31:365–8.
doi: 10.1093/rheumatology/31.6.365
6. Terslev L, Torp-Pedersen S, Qvistgaard E, von der Recke P, Bliddal H. Doppler
ultrasound findings in healthy wrists and finger joints.Ann RheumDis. (2004)
63:644–8. doi: 10.1136/ard.2003.009548
7. Millot F, Clavel G, Etchepare F, Gandjbakhch F, Grados F, Saraux A, et al.
Musculoskeletal ultrasonography in healthy subjects and ultrasound criteria
for early arthritis (the ESPOIR cohort). J Rheumatol. (2011) 38:613–20.
doi: 10.3899/jrheum.100379
8. Witt M, Mueller F, Nigg A, Reindl C, Leipe J, Proft F, et al. Relevance
of grade 1 gray-scale ultrasound findings in wrists and small joints to the
assessment of subclinical synovitis in rheumatoid arthritis. Arthritis Rheum.
(2013) 65:1694–701. doi: 10.1002/art.37954
9. Rosenberg C, Arrestier S, Etchepare F, Fautrel B, Rozenberg S, Bourgeois
P. High frequency of ultrasonographic effusion in interphalangeal joints
of healthy subjects: a descriptive study. Joint Bone Spine. (2009) 76:265–7.
doi: 10.1016/j.jbspin.2008.06.017
10. Padovano I, Costantino F, Breban M, D’Agostino MA. Prevalence of
ultrasound synovial inflammatory findings in healthy subjects. Ann Rheum
Dis. (2016) 75:1819–23. doi: 10.1136/annrheumdis-2015-208103
11. Machado FS, Furtado RN, Takahashi RD, de Buosi AL, Natour J.
Sonographic cutoff values for detection of abnormalities in small, medium
and large joints: a comparative study between patients with rheumatoid
arthritis and healthy volunteers. Ultrasound Med Biol. (2015) 41:989–98.
doi: 10.1016/j.ultrasmedbio.2014.12.004
12. D’Agostino MA, Terslev L, Aegerter P, Backhaus M, Balint P, Bruyn GA,
et al. Scoring ultrasound synovitis in rheumatoid arthritis: a EULAR-
OMERACT ultrasound taskforce-Part 1: definition and development of a
standardised, consensus-based scoring system. RMD Open. (2017) 3:e000428.
doi: 10.1136/rmdopen-2016-000428
13. Soliman E. SAT0650 Musculoskeletal ultrasound in first degree relatives of
rheumatoid arthritis patients. Ann Rheum Dis. (2018) 77(Suppl. 2):1175.
doi: 10.1136/annrheumdis-2018-eular.2349
14. Soliman E, Ohrndorf S, Zehairy M, Matrawy K, Alhadidy A, Abdelati A.
Osteopontin, osteoprotegerin and musculoskeletal ultrasound findings in
first-degree relatives of rheumatoid arthritis: potential markers of preclinical
disease. Preprint. (2020). doi: 10.21203/rs.3.rs-20512/v1
15. Brulhart L, Alpízar-Rodríguez D, Nissen MS, Zufferey P, Ciubotariu I,
Fleury G, et al. Ultrasound is not associated with the presence of
systemic autoimmunity or symptoms in individuals at-risk for rheumatoid
arthritis. RMD Open. (2019) 5:e000922. doi: 10.1136/rmdopen-2019-0
00922
16. van Steenbergen HW, Aletaha D, Beaart-van de Voorde LJ, Brouwer E,
Codreanu C, Combe B, et al. Eular definition of arthralgia suspicious
for progression to rheumatoid arthritis. Ann Rheum Dis. (2017) 76:491–6.
doi: 10.1136/annrheumdis-2016-209846
17. van der VenM, van der Veer-MeerkerkM, Ten Cate DF, Rasappu N, KokMR,
Csakvari D, et al. Absence of ultrasound inflammation in patients presenting
with arthralgia rules out the development of arthritis. Arthritis Res Ther.
(2017) 19:202. doi: 10.1186/s13075-017-1405-y
18. Zufferey P, Rebell C, Benaim C, Ziswiler HR, Dumusc A, So A. Ultrasound can
be useful to predict an evolution towards rheumatoid arthritis in patients with
inflammatory polyarthralgia without anticitrullinated antibodies. Joint, Bone,
Spine. (2017) 84:299–303. doi: 10.1016/j.jbspin.2016.05.011
19. Zufferey P, Brulhart L, Tamborrini G, Finckh A, Scherer A, Moller B, et al.
Ultrasound evaluation of synovitis in RA: correlation with clinical disease
activity and sensitivity to change in an observational cohort study. Joint Bone
Spine. (2014) 81:222–7. doi: 10.1016/j.jbspin.2013.08.006
20. Ohrndorf S, Boer AC, Boeters DM, Ten Brinck RM, Burmester GR, Kortekaas
MC, et al. Do musculoskeletal ultrasound and magnetic resonance imaging
identify synovitis and tenosynovitis at the same joints and tendons? A
comparative study in early inflammatory arthritis and clinically suspect
arthralgia. Arthritis Res Ther. (2019) 21:59. doi: 10.1186/s13075-019-1824-z
21. Rakieh C, Nam JL, Hunt L, Hensor EM, Das S, Bissell LA, et al. Predicting the
development of clinical arthritis in anti-CCP positive individuals with non-
specific musculoskeletal symptoms: a prospective observational cohort study.
Ann Rheum Dis. (2015) 74:1659–66. doi: 10.1136/annrheumdis-2014-205227
22. van de Stadt LA, Bos WH, Meursinge Reynders M, Wieringa H, Turkstra F,
van der Laken CJ, et al. The value of ultrasonography in predicting arthritis
in auto-antibody positive arthralgia patients: a prospective cohort study.
Arthritis Res Ther. (2010) 12:R98. doi: 10.1186/ar3028
23. Nam JL, Hensor EM, Hunt L, Conaghan PG, Wakefield RJ, Emery P.
Ultrasound findings predict progression to inflammatory arthritis in anti-CCP
antibody-positive patients without clinical synovitis. Ann Rheum Dis. (2016)
75:2060–7. doi: 10.1136/annrheumdis-2015-208235
24. van Beers-Tas MH, Blanken AB, Nielen MMJ, Turkstra F, van der Laken CJ,
Meursinge Reynders M, et al. The value of joint ultrasonography in predicting
arthritis in seropositive patients with arthralgia: a prospective cohort study.
Arthritis Res Ther. (2018) 20:279. doi: 10.1186/s13075-018-1767-9
25. Duquenne L, Mankia K, Montoya L, Di Matteo A, Nam J, Emery P. P240 Can
ultrasound alone predict the need to treat ACPA positive individuals without
synovitis? Rheumatology. (2020) 59. doi: 10.1093/rheumatology/keaa111.234
26. Duquenne L. MK, Di Matteo A, Garcia-Montoya L, Nam J, Emery P. ACPA
positive At-risk individuals without clinical arthritis, is ultrasound sufficiently
accurate to predict progression to inflammatory arthritis? Ann Rheum Dis.
(2020) 79:260.
27. Di Matteo A, Mankia K, Duquenne L, Cipolletta E, Wakefield RJ,
Garcia-Montoya L, et al. Ultrasound erosions in the feet best predict
progression to inflammatory arthritis in anti-CCP positive at-risk
individuals without clinical synovitis. Ann Rheum Dis. (2020) 79:901–7.
doi: 10.1136/annrheumdis-2020-217215
28. Mankia K, Emery P. What can palindromic rheumatism tell us? Best Pract Res
Clin Rheumatol. (2017) 31:90–8. doi: 10.1016/j.berh.2017.09.014
29. Cabrera-Villalba S, Ramirez J, Salvador G, Ruiz-Esquide V, Hernández
MV, Inciarte-Mundo J, et al. Is there subclinical synovitis in patients
with palindromic rheumatism in the intercritical period? a clinical and
ultrasonographic study according to anticitrullinated protein antibody status.
J Rheumatol. (2014) 41:1650–5. doi: 10.3899/jrheum.131545
30. Bugatti S, Caporali R, Manzo A, Sakellariou G, Rossi S, Montecucco
C. Ultrasonographic and MRI characterisation of the palindromic
phase of rheumatoid arthritis. Ann Rheum Dis. (2012) 71:625–6.
doi: 10.1136/annrheumdis-2011-200077
31. Chen HH, Lan JL, Hung GD, Chen YM, Lan HH, Chen DY. Association
of ultrasonographic findings of synovitis with anti-cyclic citrullinated
peptide antibodies and rheumatoid factor in patients with palindromic
rheumatism during active episodes. J Ultrasound Med. (2009) 28:1193–9.
doi: 10.7863/jum.2009.28.9.1193
32. Mankia K, D’Agostino MA, Wakefield RJ, Nam JL, Mahmood W, Grainger
AJ, et al. Identification of a distinct imaging phenotype may improve the
management of palindromic rheumatism. Ann Rheum Dis. (2019) 78:43–50.
doi: 10.1136/annrheumdis-2018-214175
33. Terslev L, von der Recke P, Torp-Pedersen S, KoenigMJ, Bliddal H. Diagnostic
sensitivity and specificity of doppler ultrasound in rheumatoid arthritis. J
Rheumatol. (2008) 35:49–53.
34. Szkudlarek M, Court-Payen M, Strandberg C, Klarlund M,
Klausen T, Ostergaard M. Power Doppler ultrasonography for
assessment of synovitis in the metacarpophalangeal joints of
patients with rheumatoid arthritis: a comparison with dynamic
Frontiers in Medicine | www.frontiersin.org 7 October 2020 | Volume 7 | Article 587827
Duquenne et al. Ultrasound in At-Risk individuals
magnetic resonance imaging. Arthritis Rheum. (2001) 44:2018–23.
doi: 10.1002/1529-0131(200109)44:9&lt;2018::AID-ART350>3.0.CO;2-C
35. Wakefield RJ, Freeston JE, O’Connor P, Reay N, Budgen A, Hensor EM, et al.
The optimal assessment of the rheumatoid arthritis hindfoot: a comparative
study of clinical examination, ultrasound and high fieldMRI.Ann RheumDis.
(2008) 67:1678–82. doi: 10.1136/ard.2007.079947
36. Freeston JE, Wakefield RJ, Conaghan PG, Hensor EM, Stewart SP, Emery P. A
diagnostic algorithm for persistence of very early inflammatory arthritis: the
utility of power Doppler ultrasound when added to conventional assessment
tools. Ann Rheum Dis. (2010) 69:417–9. doi: 10.1136/ard.2008.106658
37. Iqbal K, Lendrem DW, Hargreaves B, Isaacs JD, Thompson B, Pratt
AG. Routine musculoskeletal ultrasound findings impact diagnostic
decisions maximally in autoantibody-seronegative early arthritis patients.
Rheumatology. (2019) 58:1268–73. doi: 10.1093/rheumatology/kez008
38. Nakagomi D, Ikeda K, Okubo A, Iwamoto T, Sanayama Y, Takahashi K, et al.
Ultrasound can improve the accuracy of the (2010). American College of
Rheumatology/European League against rheumatism classification criteria for
rheumatoid arthritis to predict the requirement for methotrexate treatment.
Arthritis Rheum. (2013) 65:890–8. doi: 10.1002/art.37848
39. Ji L, Deng X, Geng Y, Song Z, Zhang Z. The additional benefit of
ultrasonography to 2010 ACR/EULAR classification criteria when diagnosing
rheumatoid arthritis in the absence of anti-cyclic citrullinated peptide
antibodies. Clin Rheumatol. (2017) 36:261–7. doi: 10.1007/s10067-016-3465-9
40. Rezaei H, Torp-Pedersen S, af Klint E, Backheden M, Kisten Y, Gyori
N, et al. Diagnostic utility of musculoskeletal ultrasound in patients with
suspected arthritis–a probabilistic approach.Arthritis Res Ther. (2014) 16:448.
doi: 10.1186/s13075-014-0448-6
41. Zhang YH, Li K, Xiao J, Zhang HD, Zhang XY. Comparison of
ultrasound, radiography, and clinical investigations in the diagnosis of early
rheumatoid synovitis in patients with nonspecific musculoskeletal symptoms:
a multicenter cross-sectional study. Med Sci Monit. (2018) 24:4372–8.
doi: 10.12659/MSM.908755
42. Filer A, de Pablo P, Allen G, Nightingale P, Jordan A, Jobanputra P, et al.
Utility of ultrasound joint counts in the prediction of rheumatoid arthritis
in patients with very early synovitis. Ann Rheum Dis. (2011) 70:500–7.
doi: 10.1136/ard.2010.131573
43. Kawashiri SY, Fujikawa K, Nishino A, Okada A, Aramaki T, Shimizu
T, et al. Ultrasound-detected bone erosion is a relapse risk factor after
discontinuation of biologic disease-modifying antirheumatic drugs in patients
with rheumatoid arthritis whose ultrasound power Doppler synovitis activity
and clinical disease activity are well controlled. Arthritis Res Ther. (2017)
19:108. doi: 10.1186/s13075-017-1320-2
44. Pratt AG, Lorenzi AR, Wilson G, Platt PN, Isaacs JD. Predicting persistent
inflammatory arthritis amongst early arthritis clinic patients in the UK: is
musculoskeletal ultrasound required? Arthritis Res Ther. (2013) 15:R118.
doi: 10.1186/ar4298
45. Salaffi F, Ciapetti A, Gasparini S, Carotti M, Filippucci E, Grassi W. A
clinical prediction rule combining routine assessment and power Doppler
ultrasonography for predicting progression to rheumatoid arthritis from
early-onset undifferentiated arthritis. Clin Exp Rheumatol. (2010) 28:686–94.
46. Damjanov N, Radunovic G, Prodanovic S, Vukovic V, Milic V, Simic Pasalic
K, et al. Construct validity and reliability of ultrasound disease activity score in
assessing joint inflammation in RA: comparison with DAS-28. Rheumatology.
(2012) 51:120–8. doi: 10.1093/rheumatology/ker255
47. Naredo E, Möller I, Cruz A, Carmona L, Garrido J. Power Doppler
ultrasonographic monitoring of response to anti-tumor necrosis factor
therapy in patients with rheumatoid arthritis. Arthritis Rheum. (2008)
58:2248–56. doi: 10.1002/art.23682
48. Ribbens C, Andre B, Marcelis S, Kaye O,Mathy L, Bonnet V, et al. Rheumatoid
hand joint synovitis: gray-scale and power Doppler US quantifications
following anti-tumor necrosis factor-alpha treatment: pilot study. Radiology.
(2003) 229:562–9. doi: 10.1148/radiol.2292020206
49. Gul HL, Eugenio G, Rabin T, Burska A, Parmar R, Wu J, et al. Defining
remission in rheumatoid arthritis: does it matter to the patient? A comparison
of multi-dimensional remission criteria and patient reported outcomes.
Rheumatology. (2019) 59:613–21. doi: 10.1093/rheumatology/kez330
50. Paulshus Sundlisæter N, Aga AB, Olsen IC, Hammer HB, Uhlig T, van der
Heijde D, et al. Clinical and ultrasound remission after 6 months of treat-
to-target therapy in early rheumatoid arthritis: associations to future good
radiographic and physical outcomes. Ann Rheum Dis. (2018) 77:1421–5.
doi: 10.1136/annrheumdis-2017-212830
51. Wang L, Geng Y, Han J, Sun X, Zhang Z. A combination model to predict
relapse and successful conventional DMARDs de-escalation in rheumatoid
arthritis patients with sustained clinical remission. Clin Exp Rheumatol.
(2019) 37:120–6.
52. Han J, Geng Y, Deng X, Zhang Z. Subclinical synovitis assessed by ultrasound
predicts flare and progressive bone erosion in rheumatoid arthritis patients
with clinical remission: a systematic review and metaanalysis. J Rheumatol.
(2016) 43:2010–8. doi: 10.3899/jrheum.160193
53. Geng Y, Han J, Deng X, Zhang Z. Deep clinical remission: an optimised
target in the management of rheumatoid arthritis? Experience from an
ultrasonography study. Clin Exp Rheumatol. (2016) 34:581–6.
54. Janta I, Valor L, De la Torre I, Martínez-Estupiñán L, Nieto JC, Ovalles-Bonilla
JG, et al. Ultrasound-detected activity in rheumatoid arthritis onmethotrexate
therapy: which joints and tendons should be assessed to predict unstable
remission? Rheumatol Int. (2016) 36:387–96. doi: 10.1007/s00296-015-3409-8
55. Han J, Geng Y, Deng X, Zhang Z. Risk factors of flare in rheumatoid
arthritis patients with both clinical and ultrasonographic remission:
a retrospective study from China. Clin Rheumatol. (2017) 36:1721–7.
doi: 10.1007/s10067-017-3736-0
56. van Aken J, Heimans L, Gillet-van Dongen H, Visser K, Ronday HK,
Speyer I, et al. Five-year outcomes of probable rheumatoid arthritis treated
with methotrexate or placebo during the first year (the PROMPT study).
Ann Rheum Dis. (2014) 73:396–400. doi: 10.1136/annrheumdis-2012-2
02967
57. Gerlag DM, Safy M, Maijer KI, Tang MW, Tas SW, Starmans-Kool
MJF, et al. Effects of B-cell directed therapy on the preclinical stage of
rheumatoid arthritis: the PRAIRI study. Ann Rheum Dis. (2019) 78:179–85.
doi: 10.1136/annrheumdis-2017-212763
58. BackhausM, Ohrndorf S, Kellner H, Strunk J, Backhaus TM, HartungW, et al.
Evaluation of a novel 7-joint ultrasound score in daily rheumatologic practice:
a pilot project. Arthritis Rheum. (2009) 61:1194–201. doi: 10.1002/art.24646
59. Naredo E, Rodríguez M, Campos C, Rodríguez-Heredia JM, Medina
JA, Giner E, et al. Validity, reproducibility, and responsiveness of a
twelve-joint simplified power doppler ultrasonographic assessment of joint
inflammation in rheumatoid arthritis. Arthritis Rheum. (2008) 59:515–22.
doi: 10.1002/art.23529
60. Dale J, Stirling A, Zhang R, Purves D, Foley J, Sambrook M, et al. Targeting
ultrasound remission in early rheumatoid arthritis: the results of the TaSER
study, a randomised clinical trial. Ann Rheum Dis. (2016) 75:1043–50.
doi: 10.1136/annrheumdis-2015-208941
61. Norvang V, Brinkmann GH, Yoshida K, Lillegraven S, Aga AB, Sexton J,
et al. Achievement of remission in two early rheumatoid arthritis cohorts
implementing different treat-to-target strategies. Arthritis Rheumatol. (2020)
72:1072–81. doi: 10.1002/art.41232
62. Mankia K, Briggs C, Emery P. How are rheumatologists managing anticyclic
citrullinated peptide antibodies-positive patients who do not have arthritis? J
Rheumatol. (2020) 47:305–6. doi: 10.3899/jrheum.190211
63. Mankia K, Emery P. Preclinical rheumatoid arthritis: progress toward
prevention. Arthritis Rheumatol. (2016) 68:779–88. doi: 10.1002/art.
39603
64. Duquenne LPP, Mankia K, Nam J, Hunt L, Tan AL, Garcia-Montoya L, Emery
P. At diagnosis of rheumatoid arthritis, at-risk patients followed in ccp+ clinic
showed milder disease activity than conventionally referred patients. Ann
Rheum Dis. (2018) 77:A935. doi: 10.1136/annrheumdis-2018-eular.5704
65. Al-Laith M, Jasenecova M, Abraham S, Bosworth A, Bruce IN, Buckley
CD, et al. Arthritis prevention in the pre-clinical phase of RA with
abatacept (the APIPPRA study): a multi-centre, randomised, double-blind,
parallel-group, placebo-controlled clinical trial protocol. Trials. (2019) 20:429.
doi: 10.1186/s13063-019-3403-7
66. Bos WH, Dijkmans BA, Boers M, van de Stadt RJ, van Schaardenburg D.
Effect of dexamethasone on autoantibody levels and arthritis development in
Frontiers in Medicine | www.frontiersin.org 8 October 2020 | Volume 7 | Article 587827
Duquenne et al. Ultrasound in At-Risk individuals
patients with arthralgia: a randomised trial. Ann Rheum Dis. (2010) 69:571–4.
doi: 10.1136/ard.2008.105767
67. Strategy to Prevent the Onset of Clinically-Apparent Rheumatoid Arthritis
(StopRA). (2020). Available online at: https://www.clinicaltrials.gov/ct2/show/
NCT02603146 (accessed April 1, 2020).
68. Van Boheemen SAT, Van Beers - Tas MH, Bos WH, Marsman D, Griep
EN, Starman M, et al. Statins to prevent rheumatoid arthritis: inconclusive
results of the STAPRA trial. Ann Rheum Dis. (2020) 79(Suppl. 1):1415–6.
doi: 10.1136/annrheumdis-2020-eular.2805
69. Burgers LE, Allaart CF, Huizinga TWJ, van der Helm-van Mil AHM. Brief
report: clinical trials aiming to prevent rheumatoid arthritis cannot detect
prevention without adequate risk stratification: a trial of methotrexate versus
placebo in undifferentiated arthritis as an example. Arthritis Rheumatol.
(2017) 69:926–31. doi: 10.1002/art.40062
70. Falahee M, Finckh A, Raza K, Harrison M. Preferences of patients
and at-risk individuals for preventive approaches to rheumatoid
arthritis. Clin Ther. (2019) 41:1346–54. doi: 10.1016/j.clinthera.2019.
04.015
Conflict of Interest: KM reports personal fees from Abbvie, UCB, and Eli
Lilly, outside the submitted work and research grants from BMS, Eli Lilly. PE
reports consultant fees from BMS, AbbVie, Gilead, Galapagos, Lilly, MSD, Pfizer,
Novartis, Roche, Samsung outside the submitted work and research grants
from UCB, AbbVie, Lilly, Novartis, BMS, Pfizer, MSD, and Roche, outside the
submitted work.
The remaining authors declare that the research was conducted in the absence of
any commercial or financial relationships that could be construed as a potential
conflict of interest.
Copyright © 2020 Duquenne, Chowdhury, Mankia and Emery. This is an open-
access article distributed under the terms of the Creative Commons Attribution
License (CC BY). The use, distribution or reproduction in other forums is permitted,
provided the original author(s) and the copyright owner(s) are credited and that the
original publication in this journal is cited, in accordance with accepted academic
practice. No use, distribution or reproduction is permitted which does not comply
with these terms.
Frontiers in Medicine | www.frontiersin.org 9 October 2020 | Volume 7 | Article 587827
